Shapely Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.4/10
Best for: semaglutide at $99/month, 48% under the register median
Shapely's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Charged on top
Coaching
In the price
No insurance needed · Vetted by our editors
Paying yourself, compounded semaglutide runs from $99/month and compounded tirzepatide from $166/month, supplies included, 2-day shipping free, and 503A/503B pharmacies licensed by the state doing the filling. Medicare and major PPO insurance are taken for the brand-name drugs, which include Mounjaro, Zepbound, Ozempic and Wegovy. The founder, Dr. Justin Zaghi, MD/MBA, trained at Harvard and holds board certification in obesity medicine as well as internal medicine.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Shapely
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Shapely at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo (Verbatim from semaglutide medication page: 'Starting at $99/month'. Starter 3-month supply at lowest titration dose (...)
- What's included
- Medication · Consult · Shipping · Coaching
- Availability
- 4 states
- FDA status
- No FDA warning letter on record
How Shapely scores
Six columns, each one computed from something Shapely has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
9.7/10$99/month is 48% below the register median of $189 for compounded semaglutide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
7.5/10On the seller's own pages, a price is published before the questionnaire starts; a live video visit is required, which is slower but is the more careful intake.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
2.6/10Publishes coverage in 4 of 50 states.
Support10%
8.5/10The price covers medication, consult, shipping, coaching.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Shapely
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: 4 states
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with Shapely involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Shapely publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake requires a live video visit with a clinician, which is more than most of the register asks and slower to complete.
- 3Shapely does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping, coaching.
- Cheapest standing monthly prices on record: semaglutide $99, tirzepatide $166. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 4 of 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Shapely support, as documented
- Phone
- 424-600-8360
- hello@getshapely.com
GLP-1 medications Shapely offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Verbatim from semaglutide medication page: 'Starting at $99/month'. Starter 3-month supply at lowest titration dose ($297/quarter). Tiered: ~$139/mo (low-mid dose), ~$179/mo (high dose). Free 2-day shipping; syringes and alcohol pads included. Via state-licensed 503A/503B compounding pharmacy. A separate telehealth recurring plan ($99/mo, $49 first-month promo) is required in addition to the medication cost.
Verbatim from tirzepatide medication page: 'Starting at $166/month'. Starter dose at lowest titration. Tiered: ~$249/mo (low-mid dose), ~$299/mo (high dose). Free 2-day shipping; syringes and alcohol pads included. Via state-licensed 503A/503B compounding pharmacy. Self-pay only for compounded tirz. A separate telehealth recurring plan ($99/mo, $49 first-month promo) is required in addition to the medication cost.
Check the price yourself before you pay
Every figure here was read off Shapely's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $166 a month, 38% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping, coaching
- No FDA warning letter matched this operator when we searched our enforcement register
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- Billed separately from the monthly figure: labs
- Coverage is published for 4 states only, so this may not reach you
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Shapely charges
Shapely lists $99/month. That sits at the affordable end of what we track.
- Compounded semaglutide — $99/month
- Compounded tirzepatide — $166/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so Shapely is genuinely under the middle rather than merely advertising that it is.
TRYM Health dispenses semaglutide and tirzepatide from $96/month, which makes it the honest comparison to run before committing here.
What Shapely dispenses
Shapely prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
What we could verify
On the record: it operates in 4 states, it dispenses through an accredited compounding pharmacy, and coaching is included rather than sold on top. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want coaching bundled rather than metered
Our read
Shapely competes on price and does it without an obvious sacrifice elsewhere: $99/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
Shapely's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay Shapely
Starting at $99/month. Check today's price, then book the free consultation.
Where Shapely is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Shapely review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Shapely's current pricing
Plans start at $99/month. The free consultation is where you learn whether you qualify, and what it costs today.